The firm will take a different reimbursement strategy for the test than its prior owner Biocept, which stopped selling it after filing for bankruptcy in 2023.

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is sure to face legal challenges, experts say.

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

The company established a new protocol for the study and will advance its drug response predictor as a companion diagnostic.

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...